Product Description
Mechanisms of Action: VEGFR1 Inhibitor,VEGFR2 Inhibitor,VEGFR3 Inhibitor,PGFR Inhibitor,KITl Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Amgen
Company Location: THOUSAND OAKS CA 91320
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Non-Small-Cell Lung Cancer|Pleural Effusion|Pericardial Effusion|Pleural Cancer
Phase 2: Gastrointestinal Cancer|Gastrointestinal Stromal Tumors|Oncology Solid Tumor Unspecified|Thyroid Cancer|Non-Small-Cell Lung Cancer|Peritoneal Cancer|Fallopian Tube Cancer|Ovarian Cancer|Breast Cancer|Carcinoid Tumor|Neuroendocrine Tumors|Malignant Carcinoid Syndrome|Islet Cell Adenoma
Phase 1: Oncology Solid Tumor Unspecified|Lung Cancer|Lymphoproliferative Disorders|Lymphoma|Colorectal Cancer|Esophageal Cancer|Pancreatic Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
10G.30 | P2 |
Withdrawn |
Breast Cancer |
2015-09-01 |
|
CDR0000526256 | P2 |
Completed |
Neuroendocrine Tumors|Gastrointestinal Cancer|Carcinoid Tumor|Islet Cell Adenoma|Malignant Carcinoid Syndrome |
2014-10-01 |
|
Asian Phase 3 Study | P3 |
Terminated |
Non-Small-Cell Lung Cancer |
2014-09-01 |
|
GOG-0170L | P2 |
Terminated |
Ovarian Cancer|Peritoneal Cancer|Fallopian Tube Cancer |
2013-07-01 |